AbbVie (ABBV) stock has risen 1.7% over the past week, slipped 6.7% over the past month, yet climbed a strong 26.0% over the last twelve months. Wall Street’s analysts are moderately bullish, with a ModerateBuy consensus and forecasting upside from current levels over the next twelve months.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The average 12‑month price target stands at $253.67, compared with the last closing price of $212.40. This implies meaningful room for further gains if analysts’ projections prove correct, which keeps AbbVie firmly on the radar of investors hunting for large‑cap pharma opportunities.
Among recent views, analyst Vamil Divan of Guggenheim Securities reiterated a Buy rating on AbbVie on April 10, 2026, with a price target of $249.00. That target also signals solid upside from today’s levels and reinforces the broader positive tone surrounding the stock.
Divan updated his AbbVie model ahead of the company’s first‑quarter 2026 earnings release on April 29, expecting an in‑line quarter. His revenue and EPS forecasts of $14.65 billion and $2.57 closely track AbbVie’s guidance and sit just below consensus, mainly because he assumes the full impact of a previously announced $0.41 EPS dilution.
According to TipRanks metrics, this 4‑star analyst ranks 690 out of 12,068, with a 56.28% success rate and a 9.80% average return per rating. Never miss a stock rating. Find all the latest ratings on TipRanks’ Top Wall Street Analysts page.